Pfizer Sets Inflectra Launch Date; J&J Plans To Fight Back
Executive Summary
Pfizer commits to “late November” launch for its biosimilar version of infliximab, partnered with Celltrion, which will be the second biosimilar to reach the US market. Remicade innovator Janssen considers it an “at risk” launch and will continue patent litigation, as well as commercial tactics to protect its market.
You may also be interested in...
2Q Pharma Results Preview: Bristol, AstraZeneca, Roche, Celgene, Bayer, Merck, AbbVie & Sanofi
PD-1 inhibitor performance and the intense curiosity around AstraZeneca both for its MYSTIC trial and Soriot's faithfulness to the company are key themes at the half-year mark. Eyes are also on commercial performance for Roche's Ocrevus and Merck's anacetrapib for clarity on whether it has a commercial future.
Pfizer Will Support Inflectra Launch With Dedicated Sales Force
The company is on track to launch the first Remicade biosimilar in the US Nov. 21 using dedicated sales reps and resources from the innovative side of the business, though it will not be a traditional sales force.
Pfizer Will Support Inflectra Launch With Dedicated Sales Force
The company is on track to launch the first Remicade biosimilar in the US Nov. 21 using dedicated sales reps and resources from the innovative side of the business, though it will not be a traditional sales force.